Crul M - Search Results

1

Population pharmacokinetics of the novel anticancer agent KRN7000.

Crul M, Mathôt RA, Giaccone G, Punt CA, Rosing H, Hillebrand MX, Ando Y, Nishi N, Tanaka H, Schellens JM, Beijnen JH. Crul M, et al. Cancer Chemother Pharmacol. 2002 Apr;49(4):287-93. doi: 10.1007/s00280-001-0413-3. Epub 2002 Jan 24. Cancer Chemother Pharmacol. 2002. PMID: 11914907 Clinical Trial.

2

Attitude of healthcare professionals toward the use of complementary and alternative medication during anti-cancer therapy.

Sont OM, Rombouts MD, Crul M. Sont OM, et al. Among authors: crul m. J Oncol Pharm Pract. 2024 Jun;30(4):628-635. doi: 10.1177/10781552231179899. Epub 2023 May 31. J Oncol Pharm Pract. 2024. PMID: 37259518 Free PMC article.

3

The handling of biopharmaceuticals used in home-based therapy for cancer patients.

Hardebol L, Sikking C, Florack M, Crul M. Hardebol L, et al. Among authors: crul m. Int J Pharm Pract. 2023 May 7;31(3):298-304. doi: 10.1093/ijpp/riad008. Int J Pharm Pract. 2023. PMID: 36773007

4

Cisplatin resistance and DNA repair.

Crul M, Schellens JH, Beijnen JH, Maliepaard M. Crul M, et al. Cancer Treat Rev. 1997 Sep-Nov;23(5-6):341-66. doi: 10.1016/s0305-7372(97)90032-3. Cancer Treat Rev. 1997. PMID: 9465884 Review. No abstract available.

5

Validated method for the determination of the novel organo-ruthenium anticancer drug NAMI-A in human biological fluids by Zeeman atomic absorption spectrometry.

Crul M, van den Bongard HJ, Tibben MM, van Tellingen O, Sava G, Schellens JH, Beijnen JH. Crul M, et al. Fresenius J Anal Chem. 2001 Mar 1;369(5):442-5. doi: 10.1007/s002160000662. Fresenius J Anal Chem. 2001. PMID: 11270226 Clinical Trial.

6

Ras biochemistry and farnesyl transferase inhibitors: a literature survey.

Crul M, de Klerk GJ, Beijnen JH, Schellens JH. Crul M, et al. Anticancer Drugs. 2001 Mar;12(3):163-84. doi: 10.1097/00001813-200103000-00001. Anticancer Drugs. 2001. PMID: 11290863 Review.

7

Evaluation of the bioequivalence of tablets and capsules containing the novel anticancer agent R115777 (Zarnestra) in patients with advanced solid tumors.

Crul M, de Klerk GJ, Swart M, Weiner L, Palmer PA, Bol CJ, Beijnen JH, Schellens JH. Crul M, et al. Eur J Drug Metab Pharmacokinet. 2002 Jan-Mar;27(1):61-5. doi: 10.1007/BF03190407. Eur J Drug Metab Pharmacokinet. 2002. PMID: 11996329 Clinical Trial.

8

Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.

Crul M, de Klerk GJ, Swart M, van't Veer LJ, de Jong D, Boerrigter L, Palmer PA, Bol CJ, Tan H, de Gast GC, Beijnen JH, Schellens JH. Crul M, et al. J Clin Oncol. 2002 Jun 1;20(11):2726-35. doi: 10.1200/JCO.2002.09.116. J Clin Oncol. 2002. PMID: 12039935 Clinical Trial.

9

Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours.

Crul M, Rosing H, de Klerk GJ, Dubbelman R, Traiser M, Reichert S, Knebel NG, Schellens JH, Beijnen JH, ten Bokkel Huinink WW. Crul M, et al. Eur J Cancer. 2002 Aug;38(12):1615-21. doi: 10.1016/s0959-8049(02)00127-2. Eur J Cancer. 2002. PMID: 12142051 Clinical Trial.

10

Isocratic ion-exchange chromatographic assay for the nucleotide gemcitabine triphosphate in human white blood cells.

Sparidans RW, Crul M, Schellens JH, Beijnen JH. Sparidans RW, et al. Among authors: crul m. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Nov 25;780(2):423-30. doi: 10.1016/s1570-0232(02)00638-4. J Chromatogr B Analyt Technol Biomed Life Sci. 2002. PMID: 12401370

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

67 results

Search Page

Filters